Z-VAD-FMK
To Order Now: info@anbioq.org
![]() Z-VAD-FMK |
|||
HY-16658B | MedChemExpress | 10mg | EUR 655 |
![]() Z-VAD-FMK |
|||
abx076838-1mg | Abbexa | 1 mg | EUR 342 |
![]() Z-VAD-FMK |
|||
A1902-1 | ApexBio | 1 mg | EUR 113 |
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
![]() Z-VAD-FMK |
|||
A1902-10 | ApexBio | 10 mg | EUR 340 |
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
![]() Z-VAD-FMK |
|||
A1902-25 | ApexBio | 25 mg | EUR 514 |
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
![]() Z-VAD-FMK |
|||
A1902-5 | ApexBio | 5 mg | EUR 224 |
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
![]() Z-VAD-FMK |
|||
A1902-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 224 |
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
![]() Z-VAD(OMe)-FMK |
|||
HY-16658 | MedChemExpress | 10mg | EUR 394 |
![]() Z-VAD-FMK, cell permeable |
|||
GL1523-1MG | Glentham Life Sciences | 1 mg | EUR 275 |
![]() Z-VAD-FMK, cell permeable |
|||
GL1523-5MG | Glentham Life Sciences | 5 mg | EUR 792 |
![]() Caspase-Family Inhibitor Z-VAD-FMK |
|||
1010-100 | Biovision | EUR 196 |
![]() Caspase-Family Inhibitor Z-VAD-FMK |
|||
1010-20C | Biovision | EUR 196 |
![]() SRB-VAD-FMK [Sulforhodamine B-VAD-FMK] |
|||
13472 | AAT Bioquest | 25 Tests | EUR 132 |
![]() FITC-VAD-FMK |
|||
9497-100 | Biovision | EUR 359 |
![]() Biotin-VAD-FMK |
|||
1123-20C | Biovision | EUR 327 |
![]() FAM-VAD-FMK |
|||
13470 | AAT Bioquest | 25 Tests | EUR 132 |
![]() TF4-VAD-FMK |
|||
13471 | AAT Bioquest | 25 Tests | EUR 132 |
![]() Biotin-VAD-FMK |
|||
HY-100894 | MedChemExpress | 1mg | EUR 1014 |
![]() Z-VAD-FMK (Pan-specific caspase inhibitor) |
|||
SIH-557-1MG | Stressmarq | 1 mg | EUR 193 |
Description: The substance Z-VAD-FMK is a pan-specific caspase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is lyophilized solid or wax which is May be dissolved in DMSO (10 mg/ml). |
![]() mFluor™ 450-VAD-FMK |
|||
13475 | AAT Bioquest | 25 Tests | EUR 132 |
![]() mFluor™ 510-VAD-FMK |
|||
13476 | AAT Bioquest | 25 Tests | EUR 132 |
![]() Z-YVAD-FMK |
|||
1141-1 | Biovision | EUR 338 |
![]() Z-YVAD-FMK |
|||
1141-5 | Biovision | EUR 805 |
![]() Z-VDVAD-FMK |
|||
1142-1 | Biovision | EUR 305 |
![]() Z-VDVAD-FMK |
|||
1142-5 | Biovision | EUR 805 |
![]() Z-DEVD-FMK |
|||
1143-1 | Biovision | EUR 316 |
![]() Z-DEVD-FMK |
|||
1143-5 | Biovision | EUR 805 |
![]() Z-LEVD-FMK |
|||
1144-1 | Biovision | EUR 316 |
![]() Z-LEVD-FMK |
|||
1144-5 | Biovision | EUR 805 |
![]() Z-VEID-FMK |
|||
1146-1 | Biovision | EUR 305 |
![]() Z-VEID-FMK |
|||
1146-5 | Biovision | EUR 805 |
![]() Z-IETD-FMK |
|||
1148-1 | Biovision | EUR 327 |
![]() Z-IETD-FMK |
|||
1148-5 | Biovision | EUR 784 |
![]() Z-LEHD-FMK |
|||
1149-1 | Biovision | EUR 316 |
![]() Z-LEHD-FMK |
|||
1149-5 | Biovision | EUR 767 |
![]() Z-ATAD-FMK |
|||
1152-1 | Biovision | EUR 349 |
![]() Z-ATAD-FMK |
|||
1152-5 | Biovision | EUR 914 |
![]() Z-FA-FMK |
|||
1986-1 | Biovision | EUR 147 |
![]() Z-FA-FMK |
|||
1986-5 | Biovision | EUR 370 |
![]() Z-AEVD-FMK |
|||
B1162-1 | Biovision | EUR 338 |
![]() Z-VRPR-FMK |
|||
B1238-1000 | Biovision | EUR 914 |
![]() Z-VRPR-FMK |
|||
B1238-250 | Biovision | EUR 338 |
![]() Z-IETD-FMK |
|||
HY-101297 | MedChemExpress | 5mg | EUR 463 |
![]() Z-DEVD-FMK |
|||
HY-12466 | MedChemExpress | 10mg | EUR 393 |
![]() Z-VRPR-FMK |
|||
GL3755-1MG | Glentham Life Sciences | 1 mg | EUR 585 |
![]() Z-VRPR-FMK |
|||
GL3755-500UG | Glentham Life Sciences | 500 ug | EUR 355 |
![]() Z-DEVD-FMK |
|||
A1920-1 | ApexBio | 1 mg | EUR 113 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
![]() Z-DEVD-FMK |
|||
A1920-10 | ApexBio | 10 mg | EUR 340 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
![]() Z-DEVD-FMK |
|||
A1920-25 | ApexBio | 25 mg | EUR 514 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
![]() Z-DEVD-FMK |
|||
A1920-5 | ApexBio | 5 mg | EUR 224 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
![]() Z-DEVD-FMK |
|||
A1920-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 293 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
![]() Z-DEVD-FMK |
|||
A1920-S | ApexBio | Evaluation Sample | EUR 81 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
![]() Z-DQMD-FMK |
|||
A1921-1 | ApexBio | 1 mg | EUR 113 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
![]() Z-DQMD-FMK |
|||
A1921-10 | ApexBio | 10 mg | EUR 340 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
![]() Z-DQMD-FMK |
|||
A1921-25 | ApexBio | 25 mg | EUR 514 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
![]() Z-DQMD-FMK |
|||
A1921-5 | ApexBio | 5 mg | EUR 224 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
![]() Z-DQMD-FMK |
|||
A1921-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 432 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
![]() Z-DQMD-FMK |
|||
A1921-S | ApexBio | Evaluation Sample | EUR 81 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
![]() Z-VDVAD-FMK |
|||
A1922-1 | ApexBio | 1 mg | EUR 177 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
![]() Z-VDVAD-FMK |
|||
A1922-10 | ApexBio | 10 mg | EUR 630 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
![]() Z-VDVAD-FMK |
|||
A1922-25 | ApexBio | 25 mg | EUR 978 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
![]() Z-VDVAD-FMK |
|||
A1922-5 | ApexBio | 5 mg | EUR 398 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
![]() Z-VDVAD-FMK |
|||
A1922-S | ApexBio | Evaluation Sample | EUR 81 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
![]() Z-VEID-FMK |
|||
A1923-1 | ApexBio | 1 mg | EUR 177 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
![]() Z-VEID-FMK |
|||
A1923-10 | ApexBio | 10 mg | EUR 630 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
![]() Z-VEID-FMK |
|||
A1923-25 | ApexBio | 25 mg | EUR 978 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
![]() Z-VEID-FMK |
|||
A1923-5 | ApexBio | 5 mg | EUR 398 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
![]() Z-VEID-FMK |
|||
A1923-S | ApexBio | Evaluation Sample | EUR 81 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
![]() Z-WEHD-FMK |
|||
A1924-1 | ApexBio | 1 mg | EUR 113 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
![]() Z-WEHD-FMK |
|||
A1924-10 | ApexBio | 10 mg | EUR 340 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
![]() Z-WEHD-FMK |
|||
A1924-25 | ApexBio | 25 mg | EUR 514 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |